Introduction
Histopathological examination is currently the gold standard for the diagnosis of melanocytic lesions. However, distinguishing Spitz nevi (SN) from Spitzoid melanomas (SM) using current histopathological criteria may be very challenging and is one the most difficult areas in Dermatopathology. [1] [2] [3] [4] Some problematic cases may show overlapping features of both SN and SM and are often termed Atypical Spitzoid Neoplasms (ASN). It has been demonstrated in a number of studies that it can be difficult to predict the clinical behavior of ASN from assessment of histopathological features and the interobserver reproducibility of pathologists for the diagnosis of these tumors is generally poor. [1] [2] [3] [4] [5] Previously, we highlighted proteomic differences between the melanocytic tumor cells of SN and SM and identified a molecular signature of five peptides that could correctly classify the tumors. 6 In this study, we sought to determine whether Imaging Mass Spectrometry (IMS) could assist in the diagnosis and risk stratification of ASN by performing IMS in a large series of cases with known clinical follow-up, by comparing in each case the diagnosis rendered by IMS with the histopathological diagnosis and also correlating the diagnoses with clinical outcome.
Materials and Methods

Sample and Clinical Data Collection
We defined ASNs as melanocytic lesions with architectural and cytologic features shared by both Spitz nevi and Spitzoid melanomas, for which a definitive histopathological diagnosis of either SN or SM could not be confidently rendered by an experienced dermatopathologist. 4, [7] [8] [9] In our opinion, ASN is the most appropriate term for these lesions, since they are truly "neoplasms" and can be either benign or malignant, and "Spitzoid" describes the cytologic and architectural resemblance to Spitz nevus.
To the best of our knowledge, this is the largest study of ASNs performed to date. A total of 252 ASN cases were contributed by centers from 11 countries throughout the world and 11 centers from the US including the Yale Spitzoid Neoplasm Repository. All cases had some degree of ambiguity that prompted an original diagnosis of ASN. Although in some cases either Spitz nevus or Spitzoid melanoma was favored, such diagnoses were considered by no means reasonably certain by the experienced dermatopathologists who reviewed the cases. The entire cohort of ASN cases consisted of difficult ambiguous lesions in the gray/ borderline area. All submitted cases were reviewed by a minimum of three experienced dermatopathologists who agreed on the classification of ASN. The cases of ASN were originally diagnosed as such by the dermatopathologist(s) who contributed the case to the study. These cases were reviewed at intradepartmental consensus conference and only cases with diagnostic uncertainty were included in the study. In addition, the first author rereviewed all cases before they entered the study. Histopathological criteria used in the evaluation and classification of a lesion as an ASN included (but were not limited to) the following: asymmetry, sheet-like growth pattern, expansile nodular growth, lack of maturation, ulceration of the epidermis, presence of mitotic figures, deep or atypical mitotic figures, deep extension into the subcutis, or large size (>1 cm). Initial inclusion criteria were a histopathological diagnosis of ASN and the availability of clinical follow-up information. A total of 252 ASN cases were initially included. Due to lack of follow-up, insufficient melanocytic component to perform the analysis, or technical difficulties 150 ASN cases were subsequently excluded.
A total of 102 cases meeting all of the above criteria were identified. Clinical and histopathological parameters were recorded for all cases including patient age, gender, tumor thickness, primary tumor anatomical location, presence or absence of ulceration, and mitotic rate in accordance with the American Joint Committee on Cancer (AJCC). 10 We adopted the clinical classification used by Gerami et al 11 in their study of ASNs -the cases were categorized into 4 clinical groups on the basis of their clinical behavior (Table 1) .
Of the total cohort of 102 cases, 94 cases were in Group 1, which was further subdivided into 3 subgroups: 1a (58 cases), 1b (26 cases), and 1c (10 cases). There were 4 cases in Group 2, 1 case in Group 3, and 3 cases in Group 4. Groups 2, 3 and 4 included patients with poor clinical outcome defined as either recurrence of disease, metastasis in non-sentinel lymph node(s) and/or distant metastases and death of disease (Table 2) .
Imaging Mass Spectrometry
IMS was performed on all ASN cases using a previously published methodology in which IMS was employed to discriminate between SN and SM. 6 In brief, 5μm-thick formalinfixed, paraffin-embedded tissue sections were used from each case after de-paraffinization. On average, twenty areas of interest from the melanocytic component, each measuring 300 μm in diameter, were mapped on each slide representing a single case. The mass spectral profile was acquired for each one of these areas of interest. The resultant spectra were compared to a proteomic signature composed of 5 proteins and each area of interest was designated as either consistent with SN or consistent with SM. For each case to be diagnosed as SN or SM, an overwhelming number of the areas of interest (>66%) had to be designated by the instrument as such. A detailed description of this method and the instruments used can be found elsewhere. 6, 12 In this study we used the very same algorithm, classification method and criteria that we did in our original study. 6 A diagnosis of either SN or SM was rendered by IMS, which was then correlated with various clinicopathologic features and compared with the histopathological diagnosis and clinical outcome.
Statistical analysis
Fisher's exact test was used to compare the frequency of cases diagnosed as SM by IMS between Group 1 versus Groups 2, 3 and 4. The same analysis was also performed comparing Groups 1 and 2 versus Groups 3 and 4 and P-values were calculated. Possible associations were examined by using logistic regression analyses with the AJCC prognostic factors (patient age, gender, primary tumor anatomical location, tumor thickness, ulceration status, and mitotic rate), considered separately as predictors of clinical category (Group 1 versus groups to 2-4). The association of histopathological diagnosis and clinical outcome was also assessed using Fisher's exact test.
Results
A total of 102 ASNs with sufficient clinical follow-up data were included in the study and analyzed by IMS. The patients' ages ranged from 2 to 83 years (average 32.6). There were 53 women and 49 men. The most common primary tumor anatomical location was the lower extremity (41 cases) followed by the trunk (28 cases), the upper extremity (16 cases), and the head and neck region (16 cases). The anatomical site of one case was unknown. The tumor thickness ranged from 0.4 mm to 5.5 mm (mean 2.1). The follow-up ranged from 0.5 to 25 years (mean 7.7).
The patients were categorized in 4 clinical groups. Group 1 comprised 94 patients and included 3 categories -a, b, and c. Group 1a comprised 58 cases, in which the patients had no evidence of disease after re-excision and in which SLN biopsy was not performed. Of these 2/58 (3.4%) cases were diagnosed as SM by IMS and the rest of the cases, 56/58 (96.6%) were diagnosed as SN. In case #9, diagnosed as SM by IMS, a diagnosis of SM with depth of 3.0 mm was also favored histopathologically. The patient was alive with no evidence of disease (ANED) 15 years after the initial diagnosis.
Group 1b included 26 cases with no evidence of disease after re-excision and negative SLN biopsy. Of those 2/26 (7.7%) cases (#39 and #40) were diagnosed as SM by IMS and 24 (92.3%) cases were diagnosed as SN. In the 2 cases diagnosed as SM by IMS, a diagnosis of SM was also favored histopathologically. The lesions were 1.0 and 4.2 mm thick, respectively, and both patients were ANED at 3 and 2 years, respectively. There were 10 cases in Group 1c, which consisted of patients with positive SLN(s) but no evidence of disease after re-excision. Four cases (40%), (#41, 100, 145 and 146), were diagnosed as SM by IMS and a diagnosis of SM was favored histopathologically. The depth in these cases ranged between 1.65 and 2.45 mm (mean 2.0). All patients were ANED at 3, 1, 3 and 3 years of follow-up, respectively. The other 6/10 cases in Group 1c (#47, 106, 108, 96, 112, 148) were diagnosed as SN by IMS. Three of these patients (#47, 106 and 108) had a histopathological diagnosis favoring SM with thickness ranging between 3.25 and 3.7 mm (mean 3.5). The follow-up interval ranged between 2.5 and 13 years (mean 7.2). Patient #106, who was 12-years-old at the time of the initial histopathological diagnosis favoring SM with thickness of 3.7 mm, was ANED for 6 years until he was killed in a car accident at the age of 18. 13 respectively (mean 3.58). The follow-up period ranged between 4 and 10 years (mean 7.2) and the patients were ANED.
Clinical Group 2 included 4 patients with locoregional disease in non-sentinel lymph nodes (#33, 35, 36 and 93). Two of them, cases #33 and #36, were diagnosed as SM by IMS. A diagnosis of SM for these cases was also favored histopathologically. Patient #36, diagnosed as SM by IMS, had a follow-up of 16 years and was ANED after a single recurrence at the same site 8 years following the original diagnosis. The other 2 patients (#35 and 93) were diagnosed as SN by IMS. Patient #35, a 58-year-old man, whose lesion from the ear (depth 4.25 mm) was originally diagnosed favoring SN histopathologically, was also diagnosed as SN by IMS. This lesion was completely excised but 15 years later there was a recurrence at the site of the primary lesion, which was also excised and diagnosed histopathologically as favoring recurrent SN. A subsequent follow-up for another 10 years (25 years total) did not show any further recurrences or metastases.
Clinical Group 3 comprised 1 patient with distant metastases, case #94. A diagnosis of SM was rendered by IMS and favored histopathologically (depth 2.25 mm). The patient was alive with disease but was lost to follow-up 1 year after the initial diagnosis. In clinical Group 4 were 3 patients with distant metastases and death of disease, cases # 12, 38, 131. All cases were diagnosed as SM by IMS, and a diagnosis of SM was also favored histopathologically. The patient characteristics of the 102 cases together with the IMS diagnosis and clinical outcome are summarized in Table 3 .
The p-value comparing the frequency of IMS SM diagnosis in Group 1 versus Groups 2-4 by the Fisher's exact test was p<0.0001, indicating a very strong association between the IMS diagnosis of SM and poor clinical outcome based on clinical follow-up. We also compared the cases in Groups 1 and 2 against those in Groups 3 and 4. The Fisher's exact test showed statistically significant difference with p=0.0002. In this comparison there was also a strong association between the IMS diagnosis of SM and clinical category. For comparison, the association of histopathological diagnosis of SM and the clinical category was also statistically significant but not as strong (p=0.001 for the comparison of Group 1 vs. Groups 2-4, p=0.02 for the comparison of Groups 1 and 2 vs. Groups 3 and 4).
In 13 cases, SM was the diagnosis rendered by IMS and favored on histopathological analysis (Table 3 ). In 10 out of these 13 cases (77%), there were adverse events including SLN metastasis, positive non-sentinel lymph nodes, recurrence, distant metastases and/or death ( Figure 1 ). In 24 cases, while the histopathological examination favored SM, the IMS diagnosis was SN and the patients had no adverse clinical outcome ( Figure 2 ). In 38 cases the histopathological diagnosis was ASN (without favoring either SN or SM) while the IMS diagnosis was SN. The clinical behavior in all these cases was benign ( Figure 3) . In 26 cases, SN was favored histopathologically and a diagnosis of SN was also rendered by IMS and all of these patients were ANED (Figure 4 ).
Discussion
The 'gray' category of ASNs is artificial and relatively broad category. [2] [3] [4] [14] [15] [16] [17] Currently, based on histopathological examination and using the available histopathological criteria, we cannot categorize these cases with certainty and thus predict their behavior. 1, 8, 11, [18] [19] [20] [21] [22] IMS is a bio-analytical method for identifying the nature and spatial distribution of metabolites, peptides and proteins, DNA segments and lipids from tissue samples. It has been used to clarify the molecular signatures of various types of cancer and other diseases. [23] [24] [25] [26] Molecular signatures usually present as a unique combination of 5-20 proteins and enable a specific diagnosis. 26 Protein and peptide analysis is superior to gene expression analysis, as it represents the actual functional state of the disease/tumor rather than the potential risk of developing it. Furthermore, post-translational modification is thus also taken into account. In a recent IMS study, we identified differences on proteomic level between SN and SM. 6 Five peptides, comprising a specific proteomic signature, were differentially expressed by the melanocytic component of SN and SM in formalin-fixed, paraffin-embedded tissue samples.
In this study we have analyzed 102 ASNs, for some of which the original pathologist(s) favored SM histopathologically, while in others SN was favored. In a third group neither SN nor SM was favored histopathologically and the diagnosis remained as ASN. Clinical Groups 2, 3 and 4 included patients with "adverse" clinical outcome. All 4 patients with advanced locoregional disease, distant metastases, and/or death (in Groups 3 and 4) were correctly diagnosed as SM by IMS. The patients in Group 4 were dead of disease and the patient in Group 3 was alive with disease but lost to follow-up 1 year after diagnosis. In clinical Group 1c, 6/10 cases were diagnosed as SN by IMS. Three of these patients had a histopathological diagnosis favoring SM and the other 3 of ASN. The lesions had tumor thicknesses between 1.75 and 5.0 mm (mean 3.5 mm). The patients were ANED at a followup ranging between 2.5 and 13 years (mean 7.2). In comparison, patients with melanoma with similar thicknesses would have had a predicted lesser survival rate and disease free interval. This suggests that there may be some characteristics on molecular level that are detected by mass spectrometry but are "invisible" to standard histopathology, thus a better predictor of clinical behavior. 10 In 13 cases SM was favored on histopathological assessment and a diagnosis of SM was rendered by IMS. All of these patients with the exception of 3 patients had either a positive SLN, positive nodes in completion lymphadenectomy, recurrence, distant metastases and/or death. In 24 cases, in which SM was favored histopathologically, IMS rendered a diagnosis of SN, which correlated well with their benign clinical behavior. In additional 38 cases, diagnosed histopathologically as ASN, IMS rendered a diagnosis of SN and the clinical outcome was also benign. In these 62 cases in total, the histopathological diagnosis was either inconclusive or favored SM while IMS classified the lesions as benign SN. All of these cases had benign clinical behavior with a mean follow-up of 7.6 years. IMS appeared to be more accurate in predicting the benign character of ASNs than histopathology and correlated better with their clinical behavior. Histopathology appeared to have a tendency to overdiagnose either atypical features or malignancy. In the final group of 26 patients, in which SN was favored histopathologically, the same diagnosis was rendered by IMS. All patients were ANED with a follow-up between 5 and 16 years.
We found a strong association between the diagnosis of SM by IMS and an adverse clinical outcome when clinical Group 1 was compared to Groups 2, 3 and 4. Of different melanoma prognostic factors that we compared, only older age and greater tumor thickness were strongly associated with adverse clinical behavior and poorer outcome. IMS diagnosis showed stronger association with clinical outcome than did the histopathological diagnosis by Fisher's exact test. In addition, the diagnosis of SM by IMS was statistically strongly associated with adverse clinical behavior. IMS analysis using a proteomic signature may be able to provide reliable diagnosis as well as clinically useful and statistically significant risk assessment of ASNs, beyond the information provided by histology and other ancillary techniques.
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